Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

The following is a summary of “Neuroretinal and RPE changes and susceptibility to Age-Related Macular Degeneration: insights ...

Retinal Biologics Industry. The retinal biologics market experienced significant growth in 2021, with total revenue reaching ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Outlook Therapeutics (OTLK) has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two ...

One habit that can have a detrimental effect on your eyesight is smoking, as it can lead to vision loss and blindness.

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.